OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update
26/09/2024
T-cell activation through neo-epitopes Transforming tumor microenvironment suppressive cells into effector cells
Down regulating T effector cells to decrease immunological reactivity Up regulating regulatory T-cells to develop immune tolerance
Three proprietary drug discovery platforms, which are central to its ambitious goal to deliver next-generation first-in-class immunotherapies
Premier international pharma, clinical and academic collaborations to speed up the delivery of our product candidates to patients in need
To download the documents
You confirm that you have read our privacy policy. You can unsubscribe at any time by using the unsubscribe links.